clinical trial · NCT06132035
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Caregen Co. Ltd.·phase1·recruiting·n = 45
Age-related Wet Macular DegenerationCG-P5 peptidePlaceboAflibercept Injection [Eylea]
brief summary
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
started
Dec 22, 2023
primary completion
May 1, 2025
completion
Aug 1, 2025
last updated
Feb 7, 2025
official title
Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol